<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04764370</url>
  </required_header>
  <id_info>
    <org_study_id>WeFlow-Arch V1.0</org_study_id>
    <nct_id>NCT04764370</nct_id>
  </id_info>
  <brief_title>Guo's Aortic Arch Reconstruction: The First in Man Study of WeFlow-Arch Modular Embedded Branch Stent Graft System</brief_title>
  <official_title>Guo's Aortic Arch Reconstruction: The First in Man Study of WeFlow-Arch Modular Embedded Branch Stent Graft System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hangzhou Endonom Medtech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hangzhou Endonom Medtech Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first in man study of WeFlow-Arch Module Embedded Aorta Arch Stent Graft&#xD;
      System&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The WeFlow-Arch Moduler Embedded Aorta Arch Stent Graft System first in man study is a&#xD;
      prospective, single center, single arm trial, which will enroll a total of 15 patients. The&#xD;
      goal of this study is to evaluate the safety and efficacy of WeFlow-Arch Moduler Embedded&#xD;
      Aorta Arch Stent Graft System in the treatment of patients with lesions of the aortic arch.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of no major adverse events related to device or surgery</measure>
    <time_frame>30 days after surgery</time_frame>
    <description>Major adverse events related to device or surgery include: stroke, respiratory failure, pericardial tamponade, dissection or aneurysm rupture, paraplegia, stent occlusion, stent bend, stent displacement, thrombosis or rupture of the approach vessel, switch to open surgery, death, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Successful delivery of the stent graft conveyors to their predetermined positions, accurate positioning and successful deployment of the stent, safe removal of the delivery device outside the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate surgery success rate</measure>
    <time_frame>immediately after the surgery</time_frame>
    <description>Successful delivery of the stent graft, no major adverse events related to devices or surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The clinical success rate</measure>
    <time_frame>12 months after the surgery</time_frame>
    <description>Clinical success rate：12 months after the operation, there was no displacement of the stent, I and III endoleak requiring treatment, aneurysm enlargement or rupture, and branch stent occlusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of secondary operations within 12 months after surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The incidence rate of secondary operations within 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate within 12 months after surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Adverse event rate within 12 months after surgery.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Aortic Arch; Aneurysm, Dissecting</condition>
  <arm_group>
    <arm_group_label>WeFlow-Arch Moduler Embedded Branch Stent Graft System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>WeFlow-Ach Moduler Embedded Branch Stent Graft System</intervention_name>
    <description>The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.</description>
    <arm_group_label>WeFlow-Arch Moduler Embedded Branch Stent Graft System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 18 to 80 years old；&#xD;
&#xD;
          2. Diagnosed with aortic arch lesions requiring intervention, including true aortic arch&#xD;
             aneurysms, pseudo-aortic arch aneurysms, dissection and ulcers involving the aortic&#xD;
             arch;&#xD;
&#xD;
          3. The length of the ascending aorta is greater than 4cm (from the junction of the aortic&#xD;
             sinus tube to the proximal edge of the innominate artery)；&#xD;
&#xD;
          4. Ascending aorta diameter ≥24mm and ≤44mm；&#xD;
&#xD;
          5. The diameter of the iliac artery ≥7mm ；&#xD;
&#xD;
          6. The diameter of the innominate artery ≤24mm, and the length ≥20mm；&#xD;
&#xD;
          7. Patients able to understand the purpose of the trial, participate in the trial&#xD;
             voluntarily with informed consent form signed by the subject him/herself or his or her&#xD;
             legal representative, and willing to complete follow-up visits as required under the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with ascending aortic aneurysm, dissection, ulcer, hematoma；&#xD;
&#xD;
          2. Experienced systemic infection during past three months;&#xD;
&#xD;
          3. History of aortic valve repair or replacement；&#xD;
&#xD;
          4. History of aortic surgery or endovascular repair surgery；&#xD;
&#xD;
          5. Carotid artery is severely narrowed, calcified, clotted, twisted；&#xD;
&#xD;
          6. Right axillary artery is severely narrowed, calcified, thrombosis, twisted；&#xD;
&#xD;
          7. Heart transplant；&#xD;
&#xD;
          8. Suffered MI or stroke during past three months；&#xD;
&#xD;
          9. Class IV heart function (NYHA classification)；&#xD;
&#xD;
         10. Pregnant or breastfeeding；&#xD;
&#xD;
         11. Allergies to contrast agents；&#xD;
&#xD;
         12. Life expectancy less than 12 months。&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Guo</last_name>
    <phone>13910758706</phone>
    <email>Pla301dml@vip.sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Guo, professor</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Arch</keyword>
  <keyword>Aneurysm</keyword>
  <keyword>Dissecting</keyword>
  <keyword>Ulcers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

